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Abstract
Background: Analysis of the clinical response of extramedullary lesions in leukemic patients treated with radiation
therapy (RT) and defining the optimal dose of radiation.
Methods: Forty-two extramedullary lesions found in 24 leukemic patients treated with RT were reviewed. The
radiation was delivered usually 2 Gy/day, up to a median of 20 Gy (range: 18.0-40.8). The clinical response and
symptom palliation effect were analyzed. The factors affecting the response were also included in the analysis.
Results: After a median time of 7.9 weeks, the overall response rate was 76.2%. A complete response (CR) was
achieved in 35.7%, a partial response in 40.5%. The symptom was relieved in 85.7% sites. The overall response rate
was better in patients whose initial tumor size was smaller than 10 cm
2 (p = 0.010) or who were treated with more
than 25 Gy (p = 0.031). The overall CR rate was also higher in those who had smaller tumors (smaller than 6 cm or
30 cm
2)( p = 0.015), or when the tumor was located in soft tissue (p = 0.029).
Conclusions: Extramedullary lesions in leukemic patients can be successfully treated with RT. The tumor response
rate was excellent and symptom relief was achieved in almost all patients. There was a better response to
treatment when the tumor was small or it was located in soft tissue. Although, there was no definite correlation
between volume reduction and total dose, it seems that higher total dose more of than 25 Gy is needed for better
response.
Background
Cure of leukemia is possible for significant numbers of
patients after intensive treatment. However, clinical
extramedullary lesions (EML) in leukemic patient nega-
tively affect the prognosis [1]. EML in leukemic patients
can occur at any age and in any organ or tissue
throughout the body, especially soft tissue, skin, bones
and lymph nodes [1-4]. However, it can also occur at
other sites such as the gastrointestinal tract, genitourin-
ary tract, heart, orbit and the sanctuary area, such as the
testis and central nervous system [5-12].
The relatively rare incidence of EML has resulted in
limited treatment experience, and there are no publica-
tions on randomized trials. Therefore, therapeutic deci-
sions are usually based on retrospective studies and case
reports. Chemotherapy is the most important treatment
method [1,13,14]. However, on an individual basis, other
modalities including surgical decompression or radiation
therapy (RT) are sometimes clinically necessary
[2,3,14-16].
RT is effective and can be used for localized lesions
that cause symptoms [13-17]. However, there is no lit-
erature specifying guidelines for radiation oncologists in
the treatment of patients with EML. As a result, the
dose or fractionation schedule and radiation treatment
method varies among institutions and patients. There-
fore, we reviewed the clinical response of EML treated
by RT.
Methods
Patients and tumor characteristics
We retrospectively reviewed the database at the St.
Mary’s Hospital, College of Medicine, the Catholic Uni-
versity of Korea from between January 2003 and Decem-
ber 2008. There were 37 patients and 88 sites treated
with RT. The median follow-up time was 12.8 months
(range: 1.9-80.2). To obtain objective clinical response
results, we analyzed 24 patients and 42 sites whose fol-
low up imaging study exists. There were 11 males and
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(range: 5-69). Most of the patients had acute myeloid
leukemia (AML) as a primary disease (75.0%) and the
others were acute lymphcytic leukemia (ALL) (20.8%) or
CML (chronic myeloid leukemia) (4.2%) patients.
In seven (29.2%) patients, they developed before
achieving the first complete remission. Of these patients,
two patients had EML initially at the time of the leuke-
mia diagnosis. In eleven (45.8%) patients, EML devel-
oped as a first sign of the first leukemia relapse. Of the
rest of patients, EML developed during or after the
treatment for leukemia relapse. There were 14 patients
with a history of bone marrow transplantation and 9
patients receiving a total body irradiation for the
conditioning.
The diagnostic workup study included history taking,
physical examination and imaging studies. Computed
tomography (CT) was acquired in 13 sites and magnetic
resonance imaging (MRI) was performed for 29 sites. Of
the 42 sites, 14 (33.3%) sites were pathologically con-
firmed to granulocytic sarcoma. In the other sites, EML
was diagnosed based on clinical evidences. Nineteen
(45.2%) tumors were located in bone, which was the
most commonly affected site. Of the remaining 16
(38.1%) tumors were located in soft tissue, 5 (11.9%) in
lymph nodes and 2 (4.8%) in solid organs (one in brain,
one in testis). The initial median tumor size was 4.8 cm
(range: 1.1-15.0) or 10.1 cm
2 (range: 0.9-54.0). The
initial median tumor volume was 43.3 cm
3 (range: 1.5-
247.5). The patients and tumor characteristics are sum-
marized in Table 1.
Treatment characteristics
Radiation was delivered usually once daily at 2 Gy, up to
am e d i a no f2 0G y( r a n g e :1 8 - 4 0 . 8 )w i t h6o r1 0M V
photon beams. The daily dose was lower than 2 Gy (1.7
or 1.8 Gy) for 10 sites, 2 Gy for 31 sites and 2.5 Gy in
only one site. The overall median treatment time was
2.1 weeks (range: 0.9-6.0). Concurrent chemotherapy
was delivered during the RT in 9 sites. Four patients
received AML-like intensive chemotherapy, 3 patients
received intra-thecal chemotherapy and 2 patients
received imatinib.
Response evaluation
The size of tumors was measured on initial diagnostic
CT or MRI images. The largest tumor dimension (LD),
as well as the dimension perpendicular to it, was mea-
sured on transaxial CT or MRI images. The bidimen-
sional tumor product (BP) was calculated as a product
of the largest dimension and the dimension perpendicu-
lar to it. However, there were some limitations, such as
some tumors were large in the cranio-caudal axis. To
compensate for this problem, the tumor was contoured
with a modern radiation treatment planning system
(CorePLAN, Seoul C&J Inc., Korea) to calculate the
tumor volume.
Post-therapy CT or MRI images were checked in the
same way. Although the follow up period was not con-
sistent in all tumors, the tumor response evaluation was
performed according to RECIST criteria. The volume
reduction rate was also calculated. The clinical or thera-
peutic factors that could have influenced the response
were analyzed.
Statistical analysis
The treatment response was analyzed using the follow-
ing factors: primary disease, tumor site, the use of che-
motherapy, initial tumor size, follow up time and the
total dose. Chi-square or Fischer’s exact test were per-
formed to determine if these factors influenced the
response. Student’s t-test was used for average compari-
son, and the Kaplan and Meier method was used for
survival analysis. Linear logistic regression methods
were used to analyze the relationship between the
Table 1 Patients and tumor characteristics
Patients Characteristics No (%)
Gender
Male 11 (45.8)
Female 13 (54.2)
Age, median (range) 30 (5-69)
Primary disease
AML 18 (75.0)
ALL 5 (20.8)
CML 1 (4.2)
Disease pattern
Before 1
st remission 7 (29.2)
First manifestation of 1
st relapse 11 (45.8)
After relapse 6 (25.0)
History of SCT (+) 14 (58.3)
History of TBI (+) 9 (37.5)
Biopsy confirmed (+) 14 (33.3)
Tumor site
Bone 19 (45.2)
Soft tissue 16 (38.1)
Lymph nodes 5 (11.9)
Solid organ 2 (4.8)
Initial tumor size (LD), cm median (range) 4.8 (1.1-15.0)
Initial tumor size (BP), cm
2 median (range) 10.13 (0.88-54.0)
Initial tumor volume, cm
3 median (range) 43.3 (1.5-247.5)
Total 24 patients, 42 sites
Abbreviations: AML = Acute myeloid leukemia, ALL = Acute lymphocytic
leukemia, CML = Chronic myeloid leukemia, SCT = Stem cell transplantation,
TBI = Total body irradiation, LD = Largest dimension, BP = Bidimensional
product
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considered statistically significant at the level of p < 0.05
in a two-tailed test. SPSS ver. 12.0 for windows (SPSS
Inc, Chicago, Illinois) was used for statistical analysis.
Results
Tumor Response
The first response evaluation was performed at a median
of 1.9 weeks (range: 0-29.7) after the RT. There were 11
sites which the response evaluation was done directly
after the RT. There were 12 (28.6%) sites with a complete
response (CR) and 17 (40.5%) sites with a partial
response (PR). The response rate (CR+PR) was 69.1%.
The second response evaluation was able to be acquired
in only 20 sites. The median time was 11.7 weeks (range:
2.9-28.4) after RT. In comparison to first response eva-
luation, there were 6 sites that had a better response (PR
to CR in 3 sites, SD to PR in 3 sites), and 12 sites showed
the same results. However, two sites progressed. The one
was a tumor on the anterior rib, which showed a PR the
day after the RT (20.4 Gy in 12 fracions), but progressed
in the second evaluation which was done 18.9 weeks after
the RT. The other was a tumor on the distal femur which
showed SD in the first evaluation (6.6 weeks after RT,
19.8 Gy in 11 fractions), but progressed in second evalua-
tion (15.9 weeks after RT).
The overall response evaluation results are shown in
Table 2. The median time for overall response evalua-
tion was 7.9 weeks (range: 0-29.7). The overall CR was
at 15 (35.7%) sites, PR was at 17 (40.5%) sites and SD at
8 (19.0%) sites.
Symptom palliation
The symptom score was retrospectively evaluated in
four scales determined by reading the chart notes. The
pain or symptom was scored 0 to 3 from no pain or
symptom, to mild, moderate or severe pain or symptom.
The pain was relieved at 36 (85.7%) sites and disap-
peared at 16 (38.1%) sites. A decrease in the pain score
of more than 2 points was observed in 17 patients and a
decrease in 1 point in 19 patients. There were no signifi-
cant differences in symptom palliation among the tumor
sites (Table 3).
Factors affecting tumor response
There was no specific correlation between the initial
tumor size and total radiation dose. The Pearson R
2 was
0.046 for LD and total dose and 0.039 for BP and total
dose, which suggests that the total dose was not
increased according to initial tumor size. However, the
tumor response was differed according to the initial
tumor size and the total dose. The overall response rate
was better in patients whose initial tumor size (BP) was
smaller than 10 cm
2 or in those patients treated with
more than 25 Gy or BED10 30 Gy. Tumors received
more than 25 Gy showed a 94.1% (16/17) response rate.
In contrast, the overall response rate was only 64.0%
(16/25) with less than 25 Gy.
The overall CR rate was not affected by the total dose,
but it was lower for those who had larger tumors.
When the tumor was larger than 6 cm in LD or larger
than 30 cm
2 i nB P ,t h eC Rr a t ew a sl o w e r .O ft h e1 3
tumors larger than 6 cm only one tumor showed a CR.
However, a CR was achieved in half (14/29) of the small
tumors less than 6 cm. The tumor location was also
important in the overall CR rate. When the tumor was
located in soft tissue, a CR was better achieved than at
other sites. The factors affecting the tumor response are
listed in Table 4 and Table 5. The use of concurrent
chemotherapy did not increase the response rate.
Volume reduction rate
The initial median volume of the tumor was 43.3 cm
3.
The median volume decreased to 11.4 cm
3 and 3.3 cm
3
in the first and second response evaluations. The
Table 2 Tumor response rate (number of sites (%))
1
st response (42 sites) 2
nd response (20 sites) Overall response (42 sites)
CR 12 (28.6) (from PR group) +3 15 (35.7)
PR 17 (40.5) (from SD group) +3 17 (40.5)
SD 13 (30.9) 8 (19.0)
PD 0 (0.0) (from SD group) +2 2 (4.8)
Time after RT (weeks)* 1.9 (0.0-47.7) 11.7 (2.9-28.4) 7.9 (0.0-47.7)
Abbreviations: CR = Complete response; PR = Partial response; SD = Stable disease; PD = Progressive disease
*median (range)
Table 3 The change of pain score after RT according to
tumor sites (number of sites (%))
Decrease of pain
score
Bone Soft
tissue
Lymph
nodes
Solid
organ
≥ 2 points 6 (31.6) 8 (50.0) 2 (40.0) 1 (50.0)
1 point 10
(52.6)
7 (43.8) 1 (20.0) 1 (50.0)
No Change 3 (15.8) 1 (6.2) 2 (40.0) 0 (0.0)
Disappeared 4 (21.1) 9 (56.3) 2 (40.0) 1 (50.0)
Total 19 16 5 2
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respectively. The overall median volume reduction rate
was 74.7%. The volume increased 13.0% and 83.1% in
two sites, which were counted as a PD in response eva-
luation. There were no statistically significant factors
affecting the volume reduction rate (Table 6). Although
there was no definite linear correlation between the
total dose and volume reduction rate, the average
volume reduction rate was higher in those who received
more than 25 Gy (Figure 1).
Overall survival
The overall survival in patients with EML was poor;
only five of 24 patients are still alive. The actuarial med-
ian survival time was 11.5 months (range: 2.3-59.0) after
the diagnosis of EML. The 1 and 2-year overall survival
rate was 50.0% and 41.3%, respectively (Figure 2).
Table 4 Factors affecting in overall response rate
Factors ( 2 × 2 analysis) Response (CR + PR) Non-response (SD + PD) Total p-value
Primary disease Yes 23 4 27 0.128
AML No 9 6 15
RT site Yes 14 2 16 0.270
Soft tissue No 18 8 26
Concurrent Yes 8 1 9 1.000
Chemotherapy No 24 9 33
Initial size Yes 13 9 22 0.010*
BP ≥ 10 cm
2 No 19 1 20
Initial size Yes 14 7 21 0.277
LD ≥ 6.0 cm No 18 3 21
Follow up time Yes 23 7 30 1.000
≥ 2 weeks No 9 3 12
Total dose Yes 16 1 17 0.031*
≥ 25 Gy No 16 9 25
BED10 Yes 17 1 18 0.026*
≥ 30 Gy No 15 9 24
Abbreviations: AML = Acute myeloid leukemia, BP = Bidimensional product, LD = Largest dimension, BED = Biologic effective dose
*Statistically significant factors
Table 5 Factors affecting in overall CR rate
Factors ( 2 × 2
analysis)
CR (15
sites)
Non-CR (27
sites)
Total p-
value
Primary
disease
Yes 10 17 27 0.810
AML No 5 10 15
RT site Yes 9 7 16 0.029*
Soft tissue No 6 20 26
Concurrent Yes 3 7 10 1.000
Chemotherapy No 12 20 32
Initial size Yes 0 7 7 0.038*
BP ≥ 30 cm
2 No 15 20 35
Initial size Yes 1 12 13 0.015*
LD ≥ 6.0 cm No 14 15 29
Follow up time Yes 13 17 30 0.158
≥ 2 weeks No 2 10 12
Total dose Yes 8 9 17 0.326
≥ 25 Gy No 7 18 25
BED10 Yes 8 10 18 0.347
≥ 30 Gy No 7 17 24
Abbreviations: CR = Complete response, ML = Acute myeloid leukemia, BP =
Bidimensional product, LD = Largest dimension, BED = Biologic effective dose
*Statistically significant factors
Table 6 Factors affecting in volume reduction rate
Factors Mean Volume Reduction Rate (%) p-value
Primary disease Yes 75.0 0.077
AML No 56.9
RT site Yes 75.7 0.254
Soft tissue No 64.1
Concurrent Yes 78.7 0.248
Chemotherapy No 65.3
Initial size Yes 48.4 0.065
BP ≥ 30 cm
2 No 72.5
Initial size Yes 58.5 0.175
LD ≥ 6.0 cm No 73.0
Follow up time Yes 69.0 0.877
≥ 2 weeks No 67.3
Total dose Yes 76.6 0.178
≥ 25 Gy No 63.0
BED10 Yes 76.9 0.140
≥ 30 Gy No 62.2
Abbreviations: AML = Acute myeloid leukemia, BP = Bidimensional product, LD
= Largest dimension, BED = Biologic effective dose
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The rare incidence of EML and the variable location of
the lesions resulted in a limited clinical experience.
Although, EML can occur in any organ or tissue
throughout the body, in our study, the most common
site was the bone. Soft tissue and lymph nodes were
also the major sites of involvement.
The median survival of patients with EML in our
study was 11.5 months. It is well known that the pre-
sence of EML in leukemic patients is generally asso-
ciated with a poor clinical outcome with a shorter
survival time [1,3,14]. The development of EML may
imply that some important signaling pathways exist,
which are associated with migration of leukemic cells to
the extramedullary organs and tissues.
Therefore, even though the treatment of EML is not
well established, many authors suggest that intensive
chemotherapeutic agents are the cornerstone in the
treatment [4,13,14]. Lan reported that patients under-
going chemotherapy for EML had a significantly longer
survival than those not receiving chemotherapy [14].
Yamauchi also suggested that the use of intensive che-
motherapy can reduce the risk of subsequent develop-
ment of leukemia in non-leukemic granulocytic sarcoma
patients [4]. On the other hand, the role of RT in the
treatment of EML is not well established. Tsimberidou
reported RT does not improve the overall or failure-free
survival [13]. However, in clinical situations, other treat-
ment modalities except chemotherapy, including surgical
decompression or RT, are also necessary on an indivi-
dual basis for the management of pain and/or other
symptoms. Also in some cases, there are patients who
cannot undergo chemotherapy because of their poor
medical condition [14].
RT is preferred to surgery in many cases because it is
non-invasive and leukemic cells are known as extremely
radiosensitive. However, the optimal irradiation dose has
not been established because of the limited clinical
experience. There are some reports treated the EML
successfully with RT with or without chemotherapy
[4,7,13,14,16-22]. However, the many reports dose not
describe the radiation technique or dose. Although,
response rates of leukemic infiltrates have been reported
with doses as low as 4 Gy, the need for higher doses up
to 40 Gy in certain locations is also recognized [23,24].
In a recent report by Bakst et al. [17], they recommend
24 Gy in 12 fractions. In our study, almost all patients
received more than 20 Gy except for one patient whose
treatment was interrupted due to a poor medical condi-
tion. The overall response rate was 76.2% and the symp-
tom response rate was 85.7%, which suggests that in
almost all cases the palliation aim can be achieved with
RT. Although, there was no correlation with symptom
control and RT dose, the overall response rate was bet-
ter in those treated with more than 25 Gy (or BED10 30
Gy) or in those with an initial tumor size smaller than
10 cm
2.
A CR was achieved in one third (35.8%) of the sites
treated, and there is a higher chance of a CR when the
tumor is located in the soft tissue. However, when the
tumor is large (more than 6 cm or 30 cm
2), it seems
that a higher RT dose is needed. Some authors have
also suggested a relationship between the size of the
tumors and the total irradiation dose [24].
The limitation of this study was its retrospective study
design without controls, small case numbers and insuffi-
cient medical record of symptom change. However, this
Figure 1 The volume reduction rate according to the total
radiation dose. (a) Linear logistic regression analysis between the
total dose and volume reduction rate. (b) The box-plot of the
average volume reduction rate according to total dose.
Figure 2 The overall survival curve.
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the treatment of EML in leukemic patients.
Conclusions
In conclusion, from this retrospective study, we con-
clude that EML can be managed successfully with RT.
The tumor response rate was excellent and symptom
relief was achieved in almost all patients, at least in the
short term. Although, there was no definite correlation
between volume reduction and total dose, it seems that
a higher total dose of more than 25 Gy or BED10 30 Gy
is needed for a better response. We also suggest that a
higher total radiation dose may be needed when the
EML is large or located in non-soft tissue sites. In addi-
tion, we suggest that at least 20 Gy may be enough for
symptom palliation in leukemic patients with EML.
Further studies are needed for detailed RT dose sche-
dule depending upon the tumor size.
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